Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Nightingale Health

2,04 EUR

-1,92 %

4.678 følger denne virksomhed

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Investorkonsensus
Sammenligne
-1,92 %
-0,49 %
-7,90 %
-14,82 %
-17,41 %
-32,45 %
+93,18 %
-
-60,39 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Læs mere
Markedsværdi
124,32 mio. EUR
Aktieomsætning
10,76 t EUR
P/E (adj.) (26e)
-7,49
EV/EBIT (adj.) (26e)
-5
P/B (26e)
2,36
EV/S (26e)
11,02
Udbytteafkast, % (26e)
-
Dækning
Anbefaling
Reducer
Kursmål
2.50 EUR
Opdateret
19.09.2025
Disclaimer
Antti Siltanen
Antti Luiro
Antti Luiro, Antti Siltanen
Vis mere
Seneste analyse

Seneste analyse

Udgivelse: 19.09.2025

Seneste omfattende analyse

Udgivelse: 13.06.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
5.3
2026

Delårsrapport Q2'26

Risiko
Forretningsrisiko
Værdiansættelsesrisiko
Lav
Høj
Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Another welfare services country is piloting Nightingale's technology
Analytikerkommentar18.12.2025, 17.54 af
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health
Pressemeddelelse18.12.2025, 13.00

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health
New study on benefits of Nightingale blood test in identifying cardiovascular disease risk
Analytikerkommentar18.12.2025, 08.14 af
Antti Luiro, Antti Siltanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

Nightingale Health

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse17.12.2025, 07.30

Landmark study: Nightingale Health’s blood test can improve prevention of heart attacks and strokes by 44% compared to current clinical practice

Nightingale Health
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video16.12.2025, 07.30

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Changes in Nightingale’s management team continue
Analytikerkommentar15.12.2025, 07.59 af
Antti Luiro, Antti Siltanen

Changes in Nightingale’s management team continue

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

Nightingale Health
Selskabsmeddelelse12.12.2025, 12.55

Nightingale Health Plc restructures Management Team to accelerate healthcare business growth

Nightingale Health
Nightingale's CFO departs suddenly
Analytikerkommentar9.12.2025, 05.53 af
Antti Luiro, Antti Siltanen

Nightingale's CFO departs suddenly

The rapid change came as a surprise to us and appears to have occurred at the company's initiative, although the exact reasons remain unclear due to the concise announcement.

Nightingale Health
Selskabsmeddelelse8.12.2025, 08.35

Change in Nightingale Health Plc’s Management Team

Nightingale Health
Nightingale expands its strategic partnership with Terveystalo
Analytikerkommentar27.11.2025, 09.12 af
Antti Luiro

Nightingale expands its strategic partnership with Terveystalo

With the new agreement, Nightingale's blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it has mainly been used in health check-ups for occupational health customers.

Nightingale Health
Pressemeddelelse26.11.2025, 09.00

Terveystalo and Nightingale Health deepen strategic partnership – preventive healthcare available to all Terveystalo customers in Finland

Nightingale Health
Pressemeddelelse20.11.2025, 08.00

Nightingale Health enables access to world’s largest metabolomics dataset through UK Biobank collaboration

Nightingale Health
Selskabsmeddelelse6.11.2025, 15.10

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health
Nightingale strengthens its research offering through strategic partnership
Analytikerkommentar5.11.2025, 14.59 af
Antti Luiro, Antti Siltanen

Nightingale strengthens its research offering through strategic partnership

Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering.

Nightingale Health
Pressemeddelelse5.11.2025, 10.50

Nightingale Health partners with Alamar Biosciences to expand its unique multiomics offering with ultra-sensitive proteomics for brain health

Nightingale Health
Selskabsmeddelelse2.10.2025, 12.30

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health
Selskabsmeddelelse2.10.2025, 06.00

Nightingale Health’s Annual Report for financial year 2024–2025 has been published

Nightingale Health
Nightingale’s service expands again with a new risk prediction
Analytikerkommentar26.9.2025, 07.16 af
Antti Luiro

Nightingale’s service expands again with a new risk prediction

Nightingale Health announced on Thursday the launch of a new risk detection tool that detects a high risk of dangerously high levels of lipoprotein (a), also known as Lp(a).

Nightingale Health
Pressemeddelelse25.9.2025, 09.10

Breakthrough in cardiovascular disease risk assessment – Nightingale Health to offer Lp(a) risk detection as part of its routine health check

Nightingale Health
Nightingale 1-6'2025: Eyeing the next commercial breakthrough
Analyse19.9.2025, 11.29 af
Antti Luiro, Antti Siltanen

Nightingale 1-6'2025: Eyeing the next commercial breakthrough

In light of the earnings release, the company's high-potential international healthcare partnerships are progressing, even though the emergence of a commercial breakthrough is taking longer than we anticipated. However, the company's research segment has emerged as a near-term revenue growth driver, providing additional time to build stronger growth.

Nightingale Health
Forumopdateringer
Jeg har spurgt Teemu om nyt fra efteråret og den tidlige vinter i denne video glædelig jul til tråden! Inderes Nightingale Health: Kaupalliset aihiot kehittyvät - Inderes Aika: 22.12.2025 klo 21.13 Videolla Nightingale Healthin toimitusjohtaja Teemu Suna käy läpi yhtiön syksyn kuulumisia...
22.12.2025, 19.53
af Antti Luiro
19
Tak for interviewet. Det skrider altså fremad, men det er godt nok et langt sejt træk, præcis som det er blevet kommunikeret. Nu er målet for 2026 omkring et dusin kommercielle piloter, så mon det bliver i 2027, at man kan forvente et større antal egentlige kundeforhold, der starter...
23.12.2025, 06.40
af Puutaheinää
8
Jeg ved faktisk ikke noget, men prøver blot at diskutere åbent om de forskningsresultater, som NG selv henviser til. Det lader heller ikke til, at man her ved, hvad NG’s egen test i sidste ende koster for velfærdsområderne (hyvinvointialueet), for slet ikke at tale om de samlede ...
19.12.2025, 13.55
af Homeros
7
Pathology Asia/Innoquest-helheden ville helt sikkert have været interessant, men den blev valgt fra på spørgsmålslisten denne gang på grund af prioritering; samtalen blev i forvejen lidt lang. I forbindelse med H2-rapporten får vi en opdatering på dette med tal Jeg vil dog tro, at...
2.1.2026, 07.04
af Antti Luiro
5
@Antti_Luiro tak for interviewet. Rigtig fint med sådan et ekstraafsnit. Jeg lyttede opmærksomt igen, og det begyndte at lyde lidt bedre end første gang. Oppeja/päätelmiä: Score2+ng-omkostning ca. 1,5x-2x (masseprissætning) i forhold til blot Score2 (20-50 €) → den økonomiske fordel...
31.12.2025, 08.04
af Cle
5
@Homeros Denne Nature-artikel fra 2022 er ikke skrevet af personer ansat hos NG. Der var tale om Nature-artiklen fra 2023. Desuden glemmes det indimellem i debatten, at man med én test fra NG ikke måler risikoen for at udvikle én specifik sygdom som slutresultat, f.eks. forhøjet ...
20.12.2025, 16.25
af Monsieur
3
Jeg klamrer mig til dette numeriske ”ti pilotcases i løbet af foråret” samt målet om 50 % omsætningsvækst som en druknende til et halmstrå, selvom førstnævnte blev udtalt som et cirkatal. Det er dog ikke kun varm luft… Vi får se.
23.12.2025, 15.19
af Cle
2
Besøg forummet
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.